← stocks-llm Find companies like CV →

CAPSOVISION INC (CV)

Health Care · Capsule endoscopy and GI diagnostic imaging · NASDAQ

CapsoVision commercializes AI-powered capsule endoscopy systems with panoramic imaging for small bowel and emerging colon diagnostics, targeting gastroenterologists globally.

What CAPSOVISION INC does

CapsoVision is a global medical technology company that develops and commercializes capsule endoscopy solutions for visualizing and diagnosing abnormalities of the GI tract. The company's core product, CapsoCam Plus, is a single-use capsule endoscope with panoramic imaging for small bowel visualization, supported by cloud-based software (CapsoCloud and CapsoView) and AI-assisted pathology detection tools. CapsoVision is expanding its portfolio with CapsoCam Colon, a next-generation capsule incorporating 3D sensing for polyp detection and measurement, currently in late-stage FDA review.

Themes: ["capsule endoscopy / GI diagnostics","AI-assisted pathology detection","cloud-based medical imaging","colorectal polyp detection","small bowel visualization","pancreatic cancer screening"]

Fundamentals

Ask why CV looks like this →

Key risks (from latest filing)

["Dependence on FDA clearances for pipeline products (CapsoCam Colon and AI-enhanced CapsoCam Plus); regulatory delays or denials could materially impact growth and commercialization timelines.","Significant operating losses and negative net margins (-198.87%) with minimal revenue growth (0.32% YoY); company is unprofitable and dependent on capital to fund R&D and commercialization efforts.","Supply chain concentration risk; manufacturing relies on component suppliers and assembly partners in Asia (Taiwan and Japan), creating exposure to geopolitical disruption and supply constraints."]

See CV's biggest risks from its latest 10-Q →

Competitors & peers

Not quite? Describe exactly what you want →

Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.

Last updated 2026-07-09.

Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.